3 active not recruiting, 1 completed. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 3, Completed 1 |
| Phase 2 | 4 | Active not recruiting 3, Completed 1 |
Follow M3814: new trials by email Literature Review of M3814 trials Research Report on M3814
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 92 | 2021-01-11 | 2026-11-12 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-11-12 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-11-12 |
| Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg - Locally Advanced Rectal Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 19 | 2019-03-20 | 2023-03-21 |
Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Lymphatic Metastasis (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
National Cancer Institute (NCI) (3) · EMD Serono Research & Development Institute, Inc. (1)
United States (4) · Spain (1)
Kristen R Spencer (1) · Russell K Pachynski (1) · Sarah L Davis (1)
2018 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186691 (1), UM1CA186704 (1), UM1CA186716 (1)